"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at cisplatin and temozolomide chemotherapy for children who have glioma brain tumours (CISTEM, CNS 2004 02)
This trial was trying to find out if a combination of the chemotherapy drugs cisplatin and temozolomide improved the treatment for children with a glioma.
This trial was for children and young people from 4 to 21 years old.
Temozolomide (Temodal) is a chemotherapy drug that doctors use to treat newly diagnosed high grade glioma (astrocytoma) or to treat brain tumours that have come back after treatment. Cisplatin is also a chemotherapy drug, used for a number of different cancers.
This trial was looking at giving temozolomide and cisplatin to children over 4 years old with a high grade glioma. It recruited 2 groups of children. Children in one group were newly diagnosed. Children in the other group had glioma that had come back after treatment.
The aim of this trial was to find out how well the combination of temozolomide and cisplatin worked for children and young adults with glioma.
Summary of results
The researchers found that the drug combination of temozolomide and cisplatin did not work as well in children with a high grade glioma as it did in adults.
52 children had treatment in this trial. All of them had a glioma that was grade 3 or 4.
- In 2 children, the glioma got smaller – researchers call this a
- In 4 children, the glioma did get smaller, but not by very much – researchers call this a
- All 6 responses were in children who were newly diagnosed
- In all the other children taking part, the glioma continued to grow
As this treatment had a response rate of only 7%, the trial showed that it did not work well enough to be used for children with a high grade glioma.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Stephen Lowis
Children's Cancer and Leukaemia Group (CCLG)
National Institute for Health Research Cancer Research Network (NCRN)